Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Diabetes Metab. 2023 Aug 1;49(5):101466. doi: 10.1016/j.diabet.2023.101466. Online ahead of print.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related di...
Source: Diabetes and Metabolism - August 3, 2023 Category: Endocrinology Authors: Valeria Grancini Andrea Gramegna Laura Zazzeron Gianfranco Alicandro Laura L Porcaro Federica Piedepalumbo Chiara Lanfranchi Valeria Dacc ò Emanuela Orsi Francesco Blasi Source Type: research
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Diabetes Metab. 2023 Aug 1:101466. doi: 10.1016/j.diabet.2023.101466. Online ahead of print.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del mutation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related diabetes ...
Source: Diabetes and Metabolism - August 3, 2023 Category: Endocrinology Authors: Valeria Grancini Andrea Gramegna Laura Zazzeron Gianfranco Alicandro Laura L Porcaro Federica Piedepalumbo Chiara Lanfranchi Valeria Dacc ò Emanuela Orsi Francesco Blasi Source Type: research
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Diabetes Metab. 2023 Aug 1:101466. doi: 10.1016/j.diabet.2023.101466. Online ahead of print.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del mutation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related diabetes ...
Source: Diabetes and Metabolism - August 3, 2023 Category: Endocrinology Authors: Valeria Grancini Andrea Gramegna Laura Zazzeron Gianfranco Alicandro Laura L Porcaro Federica Piedepalumbo Chiara Lanfranchi Valeria Dacc ò Emanuela Orsi Francesco Blasi Source Type: research
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Diabetes Metab. 2023 Aug 1:101466. doi: 10.1016/j.diabet.2023.101466. Online ahead of print.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del mutation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related diabetes ...
Source: Diabetes and Metabolism - August 3, 2023 Category: Endocrinology Authors: Valeria Grancini Andrea Gramegna Laura Zazzeron Gianfranco Alicandro Laura L Porcaro Federica Piedepalumbo Chiara Lanfranchi Valeria Dacc ò Emanuela Orsi Francesco Blasi Source Type: research
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Diabetes Metab. 2023 Aug 1:101466. doi: 10.1016/j.diabet.2023.101466. Online ahead of print.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del mutation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related diabetes ...
Source: Diabetes and Metabolism - August 3, 2023 Category: Endocrinology Authors: Valeria Grancini Andrea Gramegna Laura Zazzeron Gianfranco Alicandro Laura L Porcaro Federica Piedepalumbo Chiara Lanfranchi Valeria Dacc ò Emanuela Orsi Francesco Blasi Source Type: research
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Diabetes Metab. 2023 Aug 1:101466. doi: 10.1016/j.diabet.2023.101466. Online ahead of print.ABSTRACTCystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del mutation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related diabetes ...
Source: Diabetes and Metabolism - August 3, 2023 Category: Endocrinology Authors: Valeria Grancini Andrea Gramegna Laura Zazzeron Gianfranco Alicandro Laura L Porcaro Federica Piedepalumbo Chiara Lanfranchi Valeria Dacc ò Emanuela Orsi Francesco Blasi Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
